Hep B Study

Do you want to protect yourself and others against Hepatitis B Virus?

About Hepatitis B

Hepatitis B virus (HBV) can cause inflammation of the liver and liver cancer. In Canada, vaccination against HBV has been recommended in children since the 1990s. Vaccine protection against HBV is thought to last for decades, and most new cases of HBV infection occur in adults who did not receive the vaccine.  This study vaccine is thought to be a more effective vaccine, particularly in older people and those with health problems such as diabetes and obesity.

For more information about HPV, click here.

About This Study
This is a Canada-wide, Canadian Immunization Research Network (CIRN) study sponsored by VBI Vaccines Incorporated. For a list of our participating study sites, click here.

The purpose of this study is to measure how well the immune system responds to an investigational Hepatitis B vaccine compared with a vaccine that is currently approved for use in Canada, and to measure any side effects that may occur after receiving the vaccines. Our participants’ immune responses will be tested by measuring the amount of antibodies in the blood. If the antibodies to Hepatitis B levels rise above a certain protective level after a participant receives the vaccine, they may be protected against the actual virus if exposed to it. To find out more, visit our in-depth study page here.

To find out if you are eligible to join the study, click here!